JGC
MLYS icon

J. Goldman & Co’s Mineralys Therapeutics MLYS Stock Holding History

J. Goldman & Co’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-94,101
Closed -$2.55M – 843
2026
Q1 		$2.55M Buy
94,101
+46,813
+99% +$1.37M 0.07% 287
2025
Q4 		$1.72M Buy
47,288
+3,420
+8% +$137K 0.05% 336
2025
Q3 		$1.66M Sell
43,868
-13,767
-24% -$298K 0.04% 290
2025
Q2 		$780K Sell
57,635
-120,669
-68% -$1.75M 0.02% 351
2025
Q1 		$2.83M Buy
+178,304
New +$2.05M 0.07% 262

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

J. Goldman & Co's MLYS Position: Q2 2026 in Review

J. Goldman & Co sold out of Mineralys Therapeutics (MLYS) in Q2 2026, closing a stake of 94,101 shares — an estimated $2.55M sold.

J. Goldman & Co first reported a position in MLYS in Q1 2025 and held it in 5 quarters. The position peaked at $2.83M in Q1 2025. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • J. Goldman & Co reported no remaining Mineralys Therapeutics position as of Q2 2026 after selling out during the quarter.
  • J. Goldman & Co sold 94,101 Mineralys Therapeutics shares in Q2 2026, an estimated $2.55M.
  • J. Goldman & Co first reported a position in Mineralys Therapeutics in Q1 2025 and held it in 5 quarters.
  • J. Goldman & Co's Mineralys Therapeutics position peaked at $2.83M in Q1 2025.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.